FDA had to remind stakeholders that drug development guidance is not easily written and in-house expertise has many demands on its time, even when user fee funds are supporting the projects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?